Form 4: NeuroPace CMO Sells Shares for Tax Obligations

NeuroPace Chief Medical Officer Martha Morrell disposed of 3,052 shares of common stock to cover tax withholding obligations related to a restricted stock unit award vesting.

Summary

• Martha Morrell, Chief Medical Officer of NeuroPace Inc. (NPCE), reported a transaction on August 20, 2025.
• 3,052 shares of common stock were disposed of to satisfy tax withholding obligations upon the vesting of a restricted stock unit award.
• The shares were valued at $8.66 per share for this transaction.
• Following this disposition, Morrell beneficially owns 85,174 shares of NeuroPace common stock.
• The total beneficial ownership includes 2,283 shares acquired through the NeuroPace, Inc. 2021 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The transaction is a routine insider disposition for tax purposes following RSU vesting, which is a common and expected event, neither significantly positive nor negative for the company's outlook.

Positives

• Vesting of restricted stock units indicates compensation for the Chief Medical Officer, reflecting performance or tenure.
• Acquisition of 2,283 shares through the Employee Stock Purchase Plan suggests ongoing employee investment and alignment with company performance.

Negatives

• Disposition of 3,052 shares reduces the direct beneficial ownership of the Chief Medical Officer.

Future Outlook

NA

Industry Context

This insider transaction is a routine event related to executive compensation and does not provide specific insights into broader industry trends or competitive landscape.

Related Party Transactions

• Disposition of 3,052 shares of common stock by Chief Medical Officer Martha Morrell to satisfy tax withholding obligations related to the vesting of a restricted stock unit award.

Stakeholder Impact

• Shareholders: The disposition is a routine event related to executive compensation and is unlikely to have a significant direct impact on share price or company valuation.
• Employees: The RSU vesting and ESPP acquisition highlight the company's compensation practices for executives and employees, which can influence employee morale and retention.

Key Dates

Recommendation

The Form 4 filing details a routine disposition of shares by the Chief Medical Officer to cover tax obligations associated with restricted stock unit vesting. This is a common and expected event in executive compensation and does not reflect a change in the company's operational performance or strategic direction. Therefore, it does not provide new information that would alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

NeuroPace, NPCE, Martha Morrell, Chief Medical Officer, insider transaction, Form 4, stock sale, RSU, tax withholding, employee stock purchase plan